[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-332696-105":59,"doc-detail-332696-en":134},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":127,"head_meta":129,"extra_data":131,"updated_unix":133},105,"en","menopausal-hormone-therapy-and-incidence-mortality-and-survival-of-breast-cancer-subtypes-a-prospective-cohort-study","Menopausal hormone therapy and incidence, mortality, and survival of breast cancer subtypes - a prospective cohort study","","Menopausal hormone therapy (MHT) increases postmenopausal breast cancer risk, but its impact on deaths across breast cancer subtypes is less clear. This prospective Norwegian cohort analyzed 160,881 participants with self-reported MHT use, identifying 7,844 incident cases and 721 breast cancer-specific deaths. Cox proportional hazards models estimated subtype-specific incidence, mortality, and survival associations by MHT use.",{"@graph":69,"@context":126},[70,84,105],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":40,"@type":76,"position":81},"https://docshare.wps.com/document/research-report/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/menopausal-hormone-therapy-and-incidence-mortality-and-survival-of-breast-cancer-subtypes-a-prospective-cohort-study/332696/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/menopausal-hormone-therapy-and-incidence-mortality-and-survival-of-breast-cancer-subtypes-a-prospective-cohort-study/332696.png","ImageObject",300,407,{"name":92,"@type":93},"Skyler","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-10-29","2026-09-21",true,{"@type":102,"interactionType":103,"userInteractionCount":52},"InteractionCounter",{"@type":104},"ViewAction",{"@type":106,"mainEntity":107},"FAQPage",[108,114,118,122],{"name":109,"@type":110,"acceptedAnswer":111},"What is the main research question about MHT in this study?","Question",{"text":112,"@type":113},"Whether menopausal hormone therapy use is associated with the incidence, subtype-specific mortality, and survival of intrinsic-like breast cancer subtypes.","Answer",{"name":115,"@type":110,"acceptedAnswer":116},"How was the association between MHT and outcomes analyzed?",{"text":117,"@type":113},"The study used Cox proportional hazard regression to estimate hazard ratios with 95% confidence intervals for incidence, mortality, and survival across breast cancer subtypes.",{"name":119,"@type":110,"acceptedAnswer":120},"What did the results show regarding breast cancer risk?",{"text":121,"@type":113},"MHT use was associated with increased risk of overall, luminal A-like, and luminal B-like breast cancer, with higher risks among current estrogen-progestin therapy users versus never users.",{"name":123,"@type":110,"acceptedAnswer":124},"Did MHT use worsen overall survival among patients with breast cancer?",{"text":125,"@type":113},"No. Prediagnostic MHT use was not associated with worse overall breast cancer survival, and it was inversely associated with survival from triple-negative breast cancer.","https://schema.org",{"og:url":83,"og:type":128,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":130,"canonical":83},"index,follow",{"doc_id":132,"site_id":62},332696,1790666518,{"code":4,"msg":5,"data":135},{"doc_id":132,"user_id":136,"nickname":92,"user_avatar":137,"doc_module":4,"category_id":39,"category_name":40,"doc_title":65,"doc_description":67,"doc_content":138,"file_id":139,"file_url":140,"file_type":141,"file_size":142,"view_count":52,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":143,"language":144,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":145,"faqs":146,"seo_title":147,"seo_description":67,"update_tm":148,"read_time":149,"preview_page_count":4},2336464648746,"https://ap-avatar.wpscdn.com/davatar_276721f389ce27ea32af1340a28f341c","Busund et al. Breast Cancer Research (2024) 26:151  \n[https://doi.org/10.1186/s13058-024-01897-4](https://doi.org/10.1186/s13058-024-01897-4)  \nBreast Cancer Research  \n RESEARCH Open Access  \nMenopausal hormone therapy  \nand incidence, mortality, and survival of breast cancer subtypes: a prospective cohort study  \nMarit Busund1*, Giske Ursin2,3,4, Eiliv Lund1, Sairah Lai Fa Chen1 and Charlotta Rylander 1  \nAbstract  \nBackground Menopausal hormone therapy (MHT) is associated with an increased risk of postmenopausal breast cancer, predominantly the luminal A-like subtype. The impact of MHT on deaths from breast cancer subtypes is  \nless understood. This study aimed to explore associations between MHT use and the incidence, mortality, and survival of intrinsic-like breast cancer subtypes.  \nMethods Data from 160,881 participants with self-reported MHT use from the prospective Norwegian Women and Cancer Study were analyzed. Among them, 7,844 incident breast cancer cases, and 721 breast cancer-specific deaths occurred. Cox proportional hazard regression was performed to calculate hazard ratios (HRs) with 95% confidence intervals (CIs) for the association between MHT use and the incidence, mortality, and survival of breast cancer subtypes.  \nResults MHT use was associated with increased risk of overall, luminal A-like, and luminal B-like breast cancer,  \nwith respective HRs of 1.44 (95% CI 1.36–1. 52), 1.41 (95% CI 1.31–1. 52), and 1.23 (95% CI 1.09–1.40) among current estrogen-progestin therapy (EPT) users compared with never users. The risk increased by 4%, 4%, and 2% per year of EPT use for overall, luminal A-like, and luminal B-like breast cancers, respectively. MHT use was also associated with increased risk of overall and luminal A-like breast cancer mortality, with HRs 1. 61%(95% CI 1.36–1. 91) and 2. 15%(95% CI 1.51–3. 05) increased risk among current EPT users compared with non-users. Among patients with breast cancer, pre-diagnostic MHT use was not associated with worse survival from overall breast cancer but was inversely associated with survival from triple-negative breast cancer (TNBC; HR death 0.41; 95% CI 0.24–0.73 among current users). Results varied significantly according to tumor subtype (pheterogeneity = 0.02) .  \nConclusions Our study suggests that MHT use increases the risk of incident and fatal overall and luminal A-like, and incident luminal B-like breast cancer but does not decrease overall survival among patients with breast cancer. Further research is needed to elucidate the mechanisms underlying MHT use and breast cancer lethality, and to explore whether MHT use among patients with TNBC is indeed free from harm.  \nKeywords Menopausal hormone therapy, Breast cancer subtypes, Incidence, Mortality, Survival  \n*Correspondence: Marit Busund [marit.k.busund@uit. no](marit.k.busund@uit. no)  \nFull list of author information is available at the end of the article  \n© The Author(s) 2024. Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit [http://creativecommons.org/licenses/by/4.0/](http://creativecommons.org/licenses/by/4.0/.)[.](http://creativecommons.org/licenses/by/4.0/.)  \nBusund et al. Breast Cancer Research (2024) 26:151  \nBackground  \nBreast cancer is a heterogeneo","cbCaijB9RGXegYls","https://ap.wps.com/l/cbCaijB9RGXegYls","pdf",754017,13,"English","# Abstract\n## Background\n## Methods\n## Results\n## Conclusions\n# Background\n## Intrinsic-like breast cancer subtypes\n## Evidence on MHT risk and conflicting mortality findings","[{\"question\":\"What is the main research question about MHT in this study?\",\"answer\":\"Whether menopausal hormone therapy use is associated with the incidence, subtype-specific mortality, and survival of intrinsic-like breast cancer subtypes.\"},{\"question\":\"How was the association between MHT and outcomes analyzed?\",\"answer\":\"The study used Cox proportional hazard regression to estimate hazard ratios with 95% confidence intervals for incidence, mortality, and survival across breast cancer subtypes.\"},{\"question\":\"What did the results show regarding breast cancer risk?\",\"answer\":\"MHT use was associated with increased risk of overall, luminal A-like, and luminal B-like breast cancer, with higher risks among current estrogen-progestin therapy users versus never users.\"},{\"question\":\"Did MHT use worsen overall survival among patients with breast cancer?\",\"answer\":\"No. Prediagnostic MHT use was not associated with worse overall breast cancer survival, and it was inversely associated with survival from triple-negative breast cancer.\"}]","Menopausal hormone therapy and incidence, mortality, and survival of breast cancer subtypes - a prospective cohort study | PDF",1789999111,33]